Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Related Articles


Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase…

Hiroshi Watanabe,

Citation: European Cardiology Review 2018;13(1):35–7.

Direct Oral Anticoagulants: A Quick Guide

Julia Sikorska, James Uprichard,

Citation: European Cardiology Review 2017;12(1):40–5.

Pulmonary Hypertension

Brendan P Madden,

Citation: European Cardiology Review 2015;10(1):9–11

A Practical Clinical Approach to the Diagnosis and Treatment of Patients…

Brendan P Madden,

Citation: European Cardiology Review 2015;10(2):102–7